NCT00219791已完成2 期
Study of Recombinant Carboxypeptidase G2 (CPG2) for the Management of Patients With Delayed Methotrexate (MTX) Clearance or Intrathecal MTX Overdosage
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
- 主要终点
- Reduction in serum MTX concentration
研究概览
简要总结
To evaluate the safety and efficacy of glucarpidase in patients with impaired methotrexate (MTX) clearance owing to MTX-induced renal failure following high-dose MTX therapy, or with intrathecal MTX overdose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent by patient or legally valid representative
- •Patients receiving high-dose MTX (>1 g/m2 body surface area (BSA) given as an infusion over 24 hours) for the treatment of ALL, NHL or a solid tumour (e.g. osteosarcoma)
- •Age ≥ 18 years
- •Serum MTX >5 µmol/L 42 hours or later after the start of MTX infusion, or serum MTX >1 μmol/L 42 hours or later after the start of MTX infusion together with renal insufficiency, or serum MTX >0.4 µmol/L 48 hours or later after the start of MTX infusion together with renal insufficiency. Renal insufficiency was defined as serum creatinine >1.5 × the upper limit of normal (ULN) and/or oliguria (urine output < 500 mL/24 hours despite adequate hydration, diuretics and alkalinisation).
排除标准
- •Pregnant or lactating females
- •Unwillingness of patient or relative/legal representative to give informed consent
结局指标
主要结局
Reduction in serum MTX concentration
次要结局
- Mortality
- serum blood-urea-nitrogen
- serum creatinine
- creatinine clearance
- haematology (complete blood count and differential)
- biochemistry (electrolytes, SGOT, SGPT, alkaline phosphatase, bilirubin, total protein)
- urinalysis (dip-stick)
- MTX-related toxicity
- Adverse events
研究者
研究点 (2)
Loading locations...
相似试验
暂停
2 期
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive LymphomaLymphomaNCT04668768Fox Chase Cancer Center3
已完成
2 期
OP-07-001 studyPatients who presented delayed excretion of MTX after HD-MTX administrationJPRN-jRCT2080225030Ohara Pharmaceutical Co., Ltd.4
已完成
3 期
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALLAcute Lymphoblastic Leukemia (ALL)NCT01305655Nordic Society for Pediatric Hematology and Oncology47
已完成
1 期
A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal DysfunctionKidney DiseasesNCT00001298National Cancer Institute (NCI)10
已完成
4 期
Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled GoutGoutNCT03994731Amgen152